Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Clinical Medicine / 臨床醫學研究所
  4. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
 
  • Details

Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan

Journal
Journal of the Formosan Medical Association
Journal Volume
117
Journal Issue
6
Pages
497-504
Date Issued
2018
Author(s)
Hsieh M.-H.
Yeh M.-L.
TUNG-HUNG SU  orcid-logo
Liu T.-W.
Huang C.-F.
Huang C.-I.
Wang S.-C.
Huang J.-F.
Dai C.-Y.
JIA-HORNG KAO  
Chuang W.-L.
PEI-JER CHEN  
CHUN-JEN LIU  
Yu M.-L.
DOI
10.1016/j.jfma.2017.06.007
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021856949&doi=10.1016%2fj.jfma.2017.06.007&partnerID=40&md5=b8ac61626898cc8a3d084892c243e402
https://scholars.lib.ntu.edu.tw/handle/123456789/568341
Abstract
Background/purpose: The role of directly-acting antivirals (DAA)-containing regimens in the treatment of patients dually-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) remains unclear. The pilot study aimed to explore the safety and efficacy of a protease inhibitor, boceprevir, in combination with peginterferon/ribavirin for HCV genotype 1 (HCV-1)/HBV dually-infected patients refractory to prior peginterferon/ribavirin. Methods: Twelve peginterferon-experienced patients dually-infected with HCV-1/HBV were assigned to receive boceprevir 800 mg, twice a day, plus peginterferon-α 2b 1.5 μg/kg/week and ribavirin 800-1400 mg/day for 36 or 48 weeks. The primary endpoint was HCV sustained virological response (SVR, HCV RNA undetectable 24 weeks after end-of-treatment). Results: Five patients terminated treatment early due to adverse events (one at week 4, one at week 46), virological failures (one non-response and one breakthrough), and patient request (n = 1). Eight patients achieved HCV SVR (66.7% in full-analysis set and 72.7% in modified intention-to-treat population). The HCV SVR rate was 71.4% (5/7) in prior relapsers, 60.0% (3/5) in prior null responder; 75% in non-cirrhotic and 50% in cirrhotic patients. All four patients of prior non-cirrhotic relapsers received 36-week regimen and achieved HCV SVR. There was no HBV-related hepatic flare. All patients experienced at least one adverse event. Two had serious adverse events. Conclusion: Boceprevir plus peginterferon/ribavirin is effective in the treatment of HCV-1/HBV dually infected patients’ refractory to prior peginterferon/ribavirin combination therapy. ? 2017
SDGs

[SDGs]SDG3

Other Subjects
boceprevir; erythropoietin; peginterferon alpha2b; ribavirin; alpha interferon; antivirus agent; macrogol; N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; peginterferon alpha2b; proline; recombinant protein; ribavirin; adult; anemia; Article; blood transfusion; clinical article; cytopenia; decompensated liver cirrhosis; disease exacerbation; drug dose reduction; drug efficacy; drug safety; drug treatment failure; drug withdrawal; dyspnea; female; fever; gastrointestinal symptom; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus genotype 1; human; infection; liver cirrhosis; male; mixed infection; neutropenia; pilot study; skin manifestation; Taiwan; treatment duration; treatment response; analogs and derivatives; combination drug therapy; complication; genetics; Hepacivirus; hepatitis B; hepatitis C; middle aged; recurrent disease; sustained virologic response; virus load; young adult; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load; Young Adult
Publisher
Elsevier B.V.
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science